Christopher Gibson Recursion Pharmaceuticals, Inc. (RXRX) insider trading activity

Christopher Gibson is Chief Executive Officer of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 736,633 shares of RXRX, which is worth approximately $5.75 Million. The most recent transaction as insider was on Aug 08, 2024, when has been sold 20,000 shares (Class A Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 737K

3.41% 3M change

6.96% 12M change

Total Value Held $5.75 Million

Christopher Gibson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 08 2024	BUY Conversion of derivative security	-	20,000 Added 2.5%	778,738 Class A Common Stock
Aug 07 2024	SELL Open market or private sale	$213,000 $7.1 p/Share	30,000 Reduced 3.8%	758,738 Class A Common Stock
Aug 07 2024	BUY Conversion of derivative security	-	30,000 Added 3.66%	788,738 Class A Common Stock
Jul 11 2024	SELL Open market or private sale	$373,500 $7.47 p/Share	50,000 Reduced 6.18%	758,738 Class A Common Stock
Jul 11 2024	BUY Conversion of derivative security	-	50,000 Added 5.82%	808,738 Class A Common Stock
Jul 10 2024	SELL Bona fide gift	-	25,000 Reduced 3.19%	758,738 Class A Common Stock
Jul 10 2024	SELL Open market or private sale	$374,000 $7.48 p/Share	50,000 Reduced 6.18%	758,738 Class A Common Stock
Jul 10 2024	BUY Conversion of derivative security	-	50,000 Added 5.82%	808,738 Class A Common Stock
Jun 06 2024	SELL Open market or private sale	$450,000 $9.0 p/Share	50,000 Reduced 6.59%	708,738 Class A Common Stock
Jun 05 2024	SELL Open market or private sale	$421,000 $8.42 p/Share	50,000 Reduced 6.18%	758,738 Class A Common Stock
Jun 05 2024	SELL Bona fide gift	-	25,000 Reduced 3.0%	808,738 Class A Common Stock
Jun 05 2024	BUY Conversion of derivative security	-	25,000 Added 2.91%	833,738 Class A Common Stock
May 15 2024	SELL Payment of exercise price or tax liability	$261,080 $10.01 p/Share	26,082 Reduced 3.12%	808,738 Class A Common Stock
May 02 2024	SELL Open market or private sale	$423,500 $8.47 p/Share	50,000 Reduced 5.65%	834,820 Class A Common Stock
May 02 2024	BUY Conversion of derivative security	-	21,296 Added 2.43%	856,116 Class A Common Stock
May 01 2024	SELL Open market or private sale	$386,500 $7.73 p/Share	50,000 Reduced 5.47%	863,524 Class A Common Stock
May 01 2024	SELL Bona fide gift	-	25,000 Reduced 2.66%	913,524 Class A Common Stock
Apr 04 2024	SELL Open market or private sale	$360,800 $9.02 p/Share	40,000 Reduced 4.09%	938,524 Class A Common Stock
Apr 03 2024	SELL Open market or private sale	$353,600 $8.84 p/Share	40,000 Reduced 3.93%	978,524 Class A Common Stock
Apr 03 2024	SELL Bona fide gift	-	25,000 Reduced 2.4%	1,018,524 Class A Common Stock
Mar 28 2024	SELL Bona fide gift	-	25,000 Reduced 2.26%	1,083,524 Class A Common Stock
Mar 28 2024	SELL Open market or private sale	$404,000 $10.1 p/Share	40,000 Reduced 3.69%	1,043,524 Class A Common Stock
Mar 06 2024	SELL Bona fide gift	-	10,000 Reduced 0.9%	1,104,919 Class A Common Stock
Mar 06 2024	SELL Open market or private sale	$430,743 $11.86 p/Share	36,319 Reduced 3.17%	1,108,524 Class A Common Stock
Mar 06 2024	BUY Conversion of derivative security	-	10,000 Added 0.89%	1,114,919 Class A Common Stock

Christopher Gibson

Chief Executive Officer

Salt Lake City, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Value

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Track Activities on RXRX

Account